Thursday, 15 October 2026European Markets

PROXIMUS And XILAM ANIMATION Have A High Dividend Yield And Return On Equity In The Communication Services Sector.

Loading stream...

(vianews) - proximus (prox.br) is among this list of stock assets with the highest dividend rate and return on equity on the communication services sector.

financial asset price forward dividend yield return on equity
proximus (prox.br) €7.62 18.47% 10.81%
xilam animation (xil.pa) €3.81 2.29% 1.96%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. proximus (prox.br)

18.47% forward dividend yield and 10.81% return on equity

proximus plc provides digital services and communication solutions in belgium and internationally. it operates through domestic, international carrier services, and telesign segments. the company offers fixed and mobile telephony, internet, and television services to residential customers and small businesses, and ict services to residential, business, and telecom wholesale markets. it also provides managed and platform, integrating networking, cloud, cybersecurity, business application, and data and artificial intelligence services. in addition, the company offers international delivery authentication and digital identity services to internet brands, digital champions, and cloud native businesses. it offers its products and services under proximus, scarlet, mobile vikings, tango, telindus, and telindus netherlands brands. the company was formerly known as belgacom sa and changed its name to proximus plc in june 2015. proximus plc was founded in 1930 and is headquartered in brussels, belgium.

earnings per share

as for profitability, proximus has a trailing twelve months eps of €1.11.

pe ratio

proximus has a trailing twelve months price to earnings ratio of 6.86. meaning, the purchaser of the share is investing €6.86 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.81%.

more news about proximus.

2. xilam animation (xil.pa)

2.29% forward dividend yield and 1.96% return on equity

xilam animation operates as an audiovisual production company in france and internationally. the company creates, produces, and distributes original programs for children and adults. it also broadcasts content on television; subscription video on demand streaming platforms, including netflix, disney +, amazon, and nbc universal; and advertising video on demand streaming platforms, such as youtube and facebook. in addition, the company produces animated, series, mini-series, and feature films. it owns the oggy, cockroaches, zig & sharko, chicky, oggy oggy in preschool, oggy next gen, les tales of lupin, moka, mr magoo, trico, and i lost my body brands. the company was incorporated in 1999 and is headquartered in paris, france.

earnings per share

as for profitability, xilam animation has a trailing twelve months eps of €0.08.

pe ratio

xilam animation has a trailing twelve months price to earnings ratio of 47.62. meaning, the purchaser of the share is investing €47.62 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 1.96%.

revenue growth

year-on-year quarterly revenue growth grew by 9.7%, now sitting on 42.01m for the twelve trailing months.

more news about xilam animation.

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com